
|Articles|August 15, 2003
Topical drop handles moderate inflammation associated with KCS
Fort Lauderdale, FL-Topical loteprednol etabonate 0.5% (Lotemax, Bausch & Lomb) instilled four times daily may be beneficial to treat patients who have keratoconjunctivitis sicca (KCS) with at least a moderate inflammatory component.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
AAO 2025: Philip J. Ferrone, MD, highlights safety and efficacy findings of gildeuretinol in Stargardt disease
2
Preclinical study suggests synaptic regeneration may offer new pathway to treat glaucoma
3
Tensions rise between STAAR and Broadwood as proposed Alcon deal nears vote
4
AAO 2025: The evolution of eye care on display at AAO 2025
5